BTK and neoplasm: Inhibitors targeting BTK for treatment of these lymphomas have shown anti-tumor activity in lymphoma models, and three BTK specific inhibitors (Ibrutinib, Acalabrutinib, and Zanubrutinib) have FDA approval and are being used as a treatment option for patients.